Global Radiopharmaceutical Market Outlook (2019 to 2027) - Featuring Mallinckrodt, Bayer & Siemens Healthineers Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Radiopharmaceutical - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

The Global Radiopharmaceutical market accounted for $3.76 billion in 2019 and is expected to reach $5.99 billion by 2027 growing at a CAGR of 6.0% during the forecast period.

Some of the key factors propelling market growth are technological advancements in the diagnostics sector, increasing prevalence of cancer, and increasing applications of molecular imaging. However, the short half-life of radioisotopes is the restraining factor for the growth of the market.

Pharmaceutical formulations that contain radioisotopes are known as radiopharmaceuticals. These are bound with the biological molecules and are targeted for the specific organs. The molecules resulting from these formulations find a wide range of applications in the therapeutic and diagnostic sectors.

By radioisotope, the Technetium-99 segment is expected to grow at a significant market share during the forecast period owing to its easy availability and extensive diagnostic applications. Based on geography, North America is anticipated to hold considerable market share during the forecast period owing to the presence of radioisotope sources in the region.

Companies Mentioned

• Lantheus Medical Imaging, Inc
• GE Healthcare
• Advanced Accelerator Applications
• Mallinckrodt
• Bayer AG
• Siemens Healthineers
• IBA Radiopharma Solutions
• Eckert & Ziegler
• Philips
• Jubilant Life Sciences Limited
• Novartis AG
• BWX Technologies, Inc.
• POLATOM
• JSC Isotope
• NTP Radioisotopes SOC Ltd
• Curium
• Australian Nuclear Science and Technology Organization (ANSTO)
• Cardinal Health Inc.
• Covidien Plc
• Positron Corporation
• Monrol Nuclear Products,Inc
• Nordion, Inc.

What the report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis, etc.
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company Profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Key Topics Covered:

1 Executive Summary

2 Preface

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Application Analysis

3.7 End User Analysis

3.8 Emerging Markets

3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Radiopharmaceutical Market, By Source

5.1 Introduction

5.2 Nuclear Reactors

5.3 Cyclotrons

6 Global Radiopharmaceutical Market, By Type

6.1 Introduction

6.2 Therapeutic

6.2.1 Alpha Emitters

6.2.2 Beta Emitters

6.2.3 Brachytherapy Isotopes

6.3 Diagnostic

6.3.1 Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals

6.3.2 Positron Emission Tomography (PET) Radiopharmaceuticals

7 Global Radiopharmaceutical Market, By Radioisotope

7.1 Introduction

7.2 Yttrium-90

7.3 Thallium-201

7.4 Technetium-99

7.5 Strontium -89

7.6 Samarium-153

7.7 Rubidium-82

7.8 Rhenium-186

7.9 Radium-223

7.10 Palladium - 103

7.11 Leutetium-177

7.12 Iridium - 192

7.13 Iodine-131

7.14 Iodine-125

7.15 Iodine-123

7.16 Indium-111

7.17 Holmium-166

7.18 Gallium-68

7.19 Gallium-67

7.20 Fluorine-18

7.21 Fludeoxyglucose - (18F-FDG)

7.22 Erbium-169

7.23 Cesium-131

7.24 Actinium-225

8 Global Radiopharmaceutical Market, By Application

8.1 Introduction

8.2 Thyroid

8.3 Theranostics

8.4 Oncology

8.5 Neurology

8.6 Neuroendocrinology

8.7 Nephrology

8.8 Lymphoma

8.9 Inflammation

8.10 Gastroenterology

8.11 Cardiology

9 Global Radiopharmaceutical Market, By End User

9.1 Introduction

9.2 Ambulatory Surgical Centers

9.3 Cancer Research Institute

9.4 Diagnostic Imaging Centers

9.5 Hospitals

10 Global Radiopharmaceutical Market, By Geography

10.1 Introduction

10.2 North America

10.3 Europe

10.4 Asia Pacific

10.5 South America

10.6 Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures

11.2 Acquisitions & Mergers

11.3 New Product Launch

11.4 Expansions

11.5 Other Key Strategies

12 Company Profiling

For more information about this report visit https://www.researchandmarkets.com/r/huilu7